HAMILTON, ON and BOSTON, May 9, 2023
/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a
clinical-stage oncology company focused on developing
next-generation radiopharmaceuticals as precision medicines, today
announced that the Company will participate in a fireside chat
presentation at the Guggenheim Healthcare Talks
Radiopharmaceuticals Day on Monday, May 15,
2023 at 10:10 a.m. ET.
Presenting on behalf of Fusion will be Chief Executive Officer
John Valliant, Ph.D.
A live webcast of the event will be available on the "Events and
Presentations" page in the "Investors & Media" section of the
Company's website at https://ir.fusionpharma.com/events-webcasts. A
replay of the webcast will be archived on the Company's website for
90 days following their respective presentation dates.
About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company
focused on developing next-generation radiopharmaceuticals as
precision medicines. Fusion connects alpha particle emitting
isotopes to various targeting molecules to selectively deliver the
alpha emitting payloads to tumors. Fusion's clinical portfolio
includes: FPI-2265 targeting prostate specific membrane antigen
(PSMA) for metastatic castration resistant prostate cancer
currently in a Phase 2 trial; FPI-1434 targeting insulin-like
growth factor 1 receptor currently in a Phase 1 trial; FPI-1966,
targeting the fibroblast growth factor receptor 3 (FGFR3),
currently in a Phase 1 trial; and FPI-2059, a small molecule
targeting neurotensin receptor 1 (NTSR1), currently in a Phase 1
trial. In addition to a robust proprietary pipeline, Fusion has a
collaboration with AstraZeneca to jointly develop novel targeted
alpha therapies (TATs) and combination programs between Fusion's
TATs and AstraZeneca's DNA Damage Response Inhibitors (DDRis) and
immuno-oncology agents. The Company recently received IND clearance
for the first novel TAT under the collaboration, which targets
EGFR-cMET. Fusion has also entered into a collaboration with Merck
to evaluate FPI-1434 in combination with Merck's KEYTRUDA®
(pembrolizumab) in patients with solid tumors expressing IGF-1R. To
support Fusion's growing pipeline of TATs, the company has signed
strategic actinium supply agreements with TRIUMF, Niowave, Inc. and
BWXT Medical.
Contact:
Amanda
Cray
Senior Director of Investor Relations & Corporate
Communications
(617) 967-0207
cray@fusionpharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-guggenheim-healthcare-talks-radiopharmaceuticals-day-301819263.html
SOURCE Fusion Pharmaceuticals